慢性胃炎患者抗幽门螺杆菌感染治疗后幽门螺杆菌感染情况分析  

Helicobacter pylori infection after anti-helicobacter pylori treatment in patients with chronic gastritis

作　　者：曹慧聪 Cao Huicong(Department of First Internal Medicine,Xintai Third People′s Hospital,Xintai 271212,China)

机构地区：[1]新泰市第三人民医院内一科,山东新泰271212

出　　处：《中国临床实用医学》2021年第4期20-24,共5页China Clinical Practical Medicine

摘　　要：目的探讨慢性胃炎患者抗幽门螺杆菌感染治疗后幽门螺杆菌感染情况及炎症因子水平变化。方法选取2017年12月至2020年12月新泰市第三人民医院内一科收治的97例慢性胃炎患者,男54例,女43例,年龄(41.78±5.64)岁,年龄范围为25~63岁。采用随机数表法将患者随机分为单药治疗组(n=48)和联合治疗组(n=49)。单药治疗组患者给予泮托拉唑钠肠溶胶囊,联合治疗组在单药治疗组基础上给予阿莫西林胶囊和呋喃唑酮片。比较两组患者的临床治疗效果,胃黏膜评分,胃泌素水平,白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)水平及幽门螺杆菌感染转阴率。结果联合治疗组有效率[93.9%(46/49)]高于单药治疗组[79.2%(38/48)],差异有统计学意义(P<0.05)。治疗前两组患者胃黏膜评分及胃泌素水平比较,差异无统计学意义(P>0.05),治疗后两组患者胃黏膜评分[(1.59±0.26)分、(0.69±0.12)分]及胃泌素水平[(100.82±9.48)ng/L、(78.42±6.40)ng/L]低于治疗前[(2.36±0.46)分、(2.39±0.44)分,(132.94±12.65)ng/L、(132.89±12.75)ng/L],且联合治疗组低于单药治疗组,差异有统计学意义(P<0.05)。治疗前两组患者IL-6、TNF-α、IL-8水平比较,差异无统计学意义(P>0.05);治疗后两组患者IL-6[(24.74±2.95)pg/ml、(17.89±2.58)pg/ml]、TNF-α[(32.76±4.54)pg/ml、(28.49±3.49)pg/ml]、IL-8水平[(35.94±5.27)pg/ml、(27.48±4.14)pg/ml]低于治疗前[(27.76±3.86)pg/ml、(27.79±3.84)pg/ml,(42.94±5.65)pg/ml、(42.89±5.75)pg/ml,(46.82±5.89)pg/ml、(46.76±5.98)pg/ml],且联合治疗组低于单药治疗组,差异有统计学意义(P<0.05)。联合治疗组幽门螺杆菌感染转阴率[100%(49/49)]高于单药治疗组[77.1%(37/48)],差异有统计学意义(P<0.05)。结论慢性胃炎患者采用抗幽门螺杆菌感染治疗后能够改善治疗效果,提高幽门螺杆菌感染转阴率,降低血清炎症因子水平,有助于减轻患者临床症状。Objective To investigate the infection of Helicobacter pylori(Hp)and the changes of inflammatory factors in patients with chronic gastritis after anti-Hp treatment.Methods A total of 97 patients with chronic gastritis admitted to the Third People′s Hospital of Xantai from December 2017 to December 2020 were selected,including 54 males and 43 females,aged(41.78±5.64)years old,ranging in age from 25 to 63 years old.The patients were randomly divided into monotherapy group(n=48)and combination therapy group(n=49)by random number table method.Patients in the monotherapy group were given pantoprazole sodium enteric-dissolved capsules,and patients in the combined treatment group were given amoxicillin capsules and furazolidone tablets on the basis of monotherapy group.Clinical treatment effect,gastric mucosa score,gastrin level,interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),interleukin-8(IL-8)levels and Hp infection conversion rate were compared between 2 groups.Results The total effective rate in the combined treatment group[93.9%(46/49)]was higher than that in the monotherapy group[79.2%(38/48)],and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in gastric mucosa score and gastrin level between 2 groups(P>0.05).After treatment,gastric mucosa score[(1.59±0.26)points,(0.69±0.12)points]and gastrin level[(100.82±9.48)ng/L,(78.42±6.40)ng/L]in 2 groups were lower than those before treatment[(2.36±0.46)points,(2.39±0.44)points].(132.94±12.65)ng/L,(132.89±12.75)ng/L],and the combination treatment group was lower than the monotherapy group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of IL-6,TNF-αand IL-8 between 2 groups(P>0.05).After treatment,the levels of IL-6[(24.74±2.95)pg/ml,(17.89±2.58)pg/ml],TNF-α[(32.76±4.54)pg/ml,(28.49±3.49)pg/ml],IL-8[(35.94±5.27)pg/ml,(27.48±4.14)pg/ml]were lower than those before treatment[(27.76±3.86)pg/ml,(27.79±3.84)pg/ml,(42.94±5

关 键 词：慢性胃炎患者 抗幽门螺杆菌感染 幽门螺杆菌感染情况 炎症因子 

分 类 号：R573.3[医药卫生—消化系统]